Associated Genetic Biomarkers
ITGAX status serves as an inclusion eligibility criteria in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain ITGAX status as an inclusion criterion, 2 are phase 2 (2 open).
Trials with ITGAX status in the inclusion eligibility criteria most commonly target hairy cell leukemia and hairy cell leukemia variant .
The most frequent alterations to serve as inclusion eligibility criteria are ITGAX Expression and ITGAX Overexpression .
Rituximab, bendamustine, cladribine, and pentostatin are the most frequent therapies in trials with ITGAX as an inclusion criteria .
Significance of ITGAX in Diseases
Hairy Cell Leukemia +
ITGAX is an inclusion criterion in 2 clinical trials for hairy cell leukemia, of which 2 are open and 0 are closed. Of the trials that contain ITGAX status and hairy cell leukemia as inclusion criteria, 2 are phase 2 (2 open) .
Hairy Cell Leukemia Variant +
ITGAX is an inclusion criterion in 1 clinical trial for hairy cell leukemia variant, of which 1 is open and 0 are closed. Of the trial that contains ITGAX status and hairy cell leukemia variant as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.